Improving survival among HIV-infected injection drug users: How should we define success?

Clinical Infectious Diseases

Volumn 45, Issue 3, 2007, Pages 377-380

  Kirk, Gregory D ^a   Vlahov, David ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; METHADONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DRUG ABUSE PATTERN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MORBIDITY; MORTALITY; NOTE; PRIORITY JOURNAL; SEROCONVERSION; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVORS;

EID: 34547135927     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/519426     Document Type: Note

References (27)

1. Muga R, Langhor K, Tor J, et al. Survival of HIV-infected injection drug users (IDUs) in the era of highly active antiretroviral therapy, relative to sex- and age-specific survival among HIV-uninfected IDUs. Clin Infect Dis 2006; 45:370-6 (in this issue).
2. Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis 2005; 41:1027-34.
3. Des Jarlais DC, Friedman SR, Marmor M, et al. Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users. AIDS 1987; 1:105-11.
4. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action on Seroconversion to AIDS and Death in Europe. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000; 355:1131-7.
5. Pezzotti P, Galai N, Vlahov D, Rezza G, Lyles CM, Astemborski J. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences, Italian Seroconversion Study. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:275-82.
6. Lloyd-Smith E, Brodkin E, Wood E, et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006; 20:445-50.
7. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163:412-20.
8. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741-9.
9. Porter K, Babiker A, Bhaskaran K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362:1267-74.
10. Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy. Swiss HIV Cohort Study. AIDS 1999; 13:2547-54.
11. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999; 22:369-78.
12. Rompalo AM, Shah N, Margolick JB, et al. Evaluation of possible effects of continued drug use on HIV progression among women. Int J STD AIDS 2004; 15:322-7.
13. Thorpe LE, Frederick M, Pitt J, et al. Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. J Acquir Immune Defic Syndr 2004; 37: 1423-30.
14. Perez-Hoyos S, Ferreros I, del Amo J, et al. Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on. AIDS 2006; 20:289-91.
15. Rodriguez-Arenas MA, Jarrin I, del Amo J, et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses 2006; 22: 715-23.
16. Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F. Mortality of intravenous drug users in Rome: a cohort study. Am J Public Health 1991; 81:1307-10.
17. Prins M, Sabin CA, Lee CA, Devereux H, Coutinho RA. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. AIDS 2000; 14:1829-37.
18. Kohli R, Lo Y, Howard AA, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 41: 864-72.
19. Wang C, Vlahov D, Galai N, et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004; 190:1046-54.
20. van Asten L, Zangerle R, Hernandez Aguado I, et al. Do HIV disease progression and HAART response vary among injecting drug users in Europe? Eur J Epidemiol 2005; 20: 795-804.
21. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280:544-6.
22. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garcia de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005; 100:981-9.
23. Vlahov D, Galai N, Safaeian M, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 2005; 161:999-1012.
24. 3. J Acquir Immune Defic Syndr 2007; 44:179-87.
25. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44: 441-6.
26. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002; 17:1-11.
27. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006; 42:1628-35.